Home Stock

Stock Research: Ipca Laboratories

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Ipca Laboratories

NSI:IPCALAB INE571A01020
70
  • Value
    29
  • Growth
    54
  • Safety
    Safety
    72
  • Combined
    56
  • Sentiment
    88
  • 360° View
    360° View
    70
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Ipca Laboratories Limited is an India-based integrated pharmaceutical company. It manufactures and markets over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs), including brands like Zerodol and Lariago. Its products are sold in over 100 countries across the globe, with 18 manufacturing units in India. In the last fiscal year, the company had a market cap of $4314 million, profits of $657 million, revenue of $1046 million, and 18043 employees.

more

ANALYSIS: With an Obermatt 360° View of 74 (better than 74% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ipca Laboratories are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Ipca Laboratories. The consolidated Growth Rank has a good rank of 52, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 52% of competitors in the same industry. The consolidated Safety Rank at 74 means that the company has a financing structure that is safer than 74% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 92, which means that professional investors are more optimistic about the stock than for 92% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 26, meaning that the share price of Ipca Laboratories is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 74% of alternative stocks in the same industry. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Sentiment
Country India
Industry Pharmaceuticals
Size Large
Website ipca.com
Index
Ipca Laboratories stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
29 43 53 55
Growth
54 95 65 25
Safety
Safety
72 40 48 91
Sentiment
88 95 14 4
360° View
360° View
70 90 41 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
68 77 19 71
Opinions Change
63 71 50 13
Pro Holdings
n/a 81 43 16
Market Pulse
65 90 9 37
Sentiment
88 95 14 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
29 43 53 55
Growth
54 95 65 25
Safety Safety
72 40 48 91
Combined
56 76 73 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
29 52 65 53
Price vs. Earnings (P/E)
37 38 45 68
Price vs. Book (P/B)
23 43 55 56
Dividend Yield
37 25 27 24
Value
29 43 53 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
46 78 90 57
Profit Growth
52 86 80 8
Capital Growth
43 62 4 58
Stock Returns
73 79 57 31
Growth
54 95 65 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
67 44 42 76
Refinancing
56 52 70 66
Liquidity
62 28 37 84
Safety Safety
72 40 48 91

Similar Stocks

Discover high‑ranked alternatives to Ipca Laboratories and broaden your portfolio horizons.

Mega Lifesciences

SET:MEGA
Country: Thailand
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Gujarat Gas

NSI:GUJGASLTD
Country: India
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Coal India

NSI:COALINDIA
Country: India
Industry: Coal & Consumable Fuels
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews